Mentice AB (publ)
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MNTC.ST research report →
Companywww.mentice.com
Mentice AB (publ) provides endovascular simulation solutions to teaching entities, healthcare systems, and medical device manufacturers. The company operates through Medical Device Industry, Healthcare Systems, and Strategic Alliances segments. It provides software modules in the areas of acute ischemic stroke intervention, atrial septal defect and patent foramen ovale occlusion, aortic valve implantation, endovascular aortic repair, below-the-knee intervention, carotid intervention, patient-specific simulation, coronary advanced and essentials, coronary intermediate, left atrial appendage occlusion, neurovascular coiling and thrombectomy, peripheral angiography, prostatic artery embolization, radiation safety, renal denervation, renal intervention, thoracic endovascular aortic repair, transarterial chemoembolization, transseptal puncture, uterine artery embolization, peripheral angiography, and vascular trauma and cardiac rhythm management, as well as supports interventionalists to transition from transfemoral to transradial access.
- CEO
- Frans Matthieu Venker
- IPO
- 2019
- Employees
- 131
- HQ
- Gothenburg, SE
Price Chart
Valuation
- Market Cap
- $433.14M
- P/E
- -20.34
- P/S
- 1.51
- P/B
- 3.51
- EV/EBITDA
- 49.21
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 40.31%
- Op Margin
- -7.76%
- Net Margin
- -7.42%
- ROE
- -17.62%
- ROIC
- -16.04%
Growth & Income
- Revenue
- $279.09M · -3.87%
- Net Income
- $-32,334,000 · -75.54%
- EPS
- $-1.15 · -59.72%
- Op Income
- $-33,060,000
- FCF YoY
- -1816.88%
Performance & Tape
- 52W High
- $21.30
- 52W Low
- $8.50
- 50D MA
- $13.40
- 200D MA
- $13.00
- Beta
- 0.64
- Avg Volume
- 15.11K
Get TickerSpark's AI analysis on MNTC.ST
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our MNTC.ST Coverage
We haven't published any research on MNTC.ST yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate MNTC.ST Report →